Is­rael’s Arkin Hold­ings launch­es sec­ond biotech fund, worth $140 mil­lion

Four years af­ter launch­ing their first biotech fund, Arkin Hold­ings is scal­ing up.

The Is­raeli in­vest­ment firm is team­ing with Phoenix Group on a $140 mil­lion fund to fu­el 10-12 com­pa­nies build­ing gene ther­a­pies, DNA and RNA-based treat­ments, or oth­er tar­get­ed drugs for dis­eases that now leave pa­tients with few oth­er op­tions. Along with Phoenix and Arkin, Is­raeli-based Migdal will al­so con­tribute cap­i­tal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER